NBP — I-Mab Stock Price, Chart & AI Report

Positive Sep 8, 2026 • 11:00 UTC GlobeNewswire Inc. • Novabridge Biosciences

NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director

NovaBridge Biosciences announced the appointment of Martin Dewhurst, a veteran healthcare executive with over 30 years of experience, to its Board of Directors as an independent director and member of both the Audit and Compensation Committees. Dewhurst brings extensive governance and strategic expertise from his tenure at McKinsey & Company and multiple board positions across biotech, biopharma, and healthcare companies.

NBP board appointment independent director governance healthcare executive audit committee compensation committee biotechnology

Sentiment note

The appointment of an experienced healthcare executive with strong governance credentials and extensive board experience across leading biotech and pharma companies strengthens NovaBridge's board oversight and strategic guidance. This is viewed positively as it enhances corporate governance and demonstrates confidence in the company's growth trajectory.

Positive Jul 24, 2026 • 21:00 UTC GlobeNewswire Inc. • Novabridge Biosciences

NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026

NovaBridge Biosciences announced its annual general meeting of shareholders will be held on September 8, 2026, at its Shanghai office. The company, a clinical-stage biopharmaceutical firm, is advancing innovative medicines including givastomig for gastric cancer and VIS-101 for retinal vascular diseases. Shareholders of record as of July 27, 2026, are entitled to attend and vote.

NBP annual general meeting shareholders biopharmaceutical givastomig VIS-101 gastric cancer clinical-stage

Sentiment note

The company is advancing multiple clinical-stage drug candidates with significant progress, including FDA Fast Track designation for givastomig and positive Phase 1b results. The pipeline includes potential first-in-class and best-in-class therapies addressing areas of unmet medical need, indicating strong development momentum and regulatory support.

Positive Dec 30, 2025 • 12:00 UTC GlobeNewswire Inc. • Na

NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026

NovaBridge Biosciences announced its inclusion in the Nasdaq Biotech Index effective December 19, 2025, and will ring the Nasdaq opening bell on January 2, 2026. The company highlighted this milestone as recognition of its strategic vision and pipeline strength as a global biotechnology platform focused on developing innovative medicines.

NBP Nasdaq Biotech Index givastomig VIS-101 biotechnology clinical development 4-1BB bispecific antibody gastric cancer

Sentiment note

The company achieved a notable milestone by being included in the Nasdaq Biotech Index, which enhances visibility and validates its position as an industry leader. Leadership expressed confidence in the company's strategic vision and pipeline strength, and the opening bell ringing ceremony represents positive market recognition.

Positive Dec 4, 2025 • 00:30 UTC GlobeNewswire Inc. • Novabridge Biosciences

NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO

NovaBridge Biosciences and ABL Bio reported positive Phase 1 dosing study results for ragistomig, a 4-1BB X PD-L1 bispecific antibody designed to treat patients resistant to checkpoint inhibitors, with extended dosing interval showing strong anti-tumor efficacy and improved safety profile.

NBP ragistomig bispecific antibody checkpoint inhibitors cancer treatment immunotherapy

Sentiment note

Reported promising clinical trial results, expanded dosing options, and potential advancement in cancer treatment

Positive Nov 21, 2025 • 01:00 UTC GlobeNewswire Inc. • Novabridge Biosciences

NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

NovaBridge's subsidiary Visara appointed Dr. Cadmus C. Rich as Chief Medical Officer and Dr. Carlos Quezada-Ruiz as Scientific Advisory Board Chair to advance VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 for treating retinal diseases.

NBP ophthalmology VIS-101 retinal diseases wet AMD clinical development

Sentiment note

Company is expanding leadership team with experienced professionals and advancing promising drug candidate VIS-101